IRulya Therapeutics Inc. Common Stock
IRLA
84 hedge funds and large institutions have $491M invested in IRulya Therapeutics Inc. Common Stock in 2020 Q4 according to their latest regulatory filings, with 21 funds opening new positions, 29 increasing their positions, 17 reducing their positions, and 16 closing their positions.
71% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 17
31% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 16
6% more funds holding
Funds holding: 79 → 84 (+5)
3.76% more ownership
Funds ownership: 56.1% → 59.86% (+3.8%)
41% less capital invested
Capital invested by funds: $827M → $491M (-$336M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
78% less call options, than puts
Call options by funds: $4.01M | Put options by funds: $17.9M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$23.8M |
| 2 |
BlackRock
New York
|
+$17.8M |
| 3 |
Morgan Stanley
New York
|
+$6.61M |
| 4 |
Millennium Management
New York
|
+$4.61M |
| 5 |
ECG
EPIQ Capital Group
San Francisco,
California
|
+$4.08M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$9.83M |
| 2 |
BC
Burleson & Co
Petaluma,
California
|
-$2.3M |
| 3 |
SSA
Schonfeld Strategic Advisors
New York
|
-$1.4M |
| 4 |
IC
Ikarian Capital
Dallas,
Texas
|
-$1.2M |
| 5 |
ECM
Endurant Capital Management
San Mateo,
California
|
-$1.09M |
IRLA Hedge Fund Activity: Q4 2020 in Review
84 of the 5,677 institutional investors tracked by Wall St. Rank reported a position in IRulya Therapeutics Inc. Common Stock (IRLA) for Q4 2020, worth a combined $491M — down 41% from $827M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new IRLA positions and 16 closed out — a net gain of 5 holders — while 29 added to existing stakes and 17 trimmed.
The largest buyer was State Street, adding an estimated $23.8M. The largest seller was Citadel Advisors, cutting an estimated $9.83M.
- 84 institutional investors held IRulya Therapeutics Inc. Common Stock (IRLA) as of Q4 2020, up from 79 in Q3 2020.
- Funds reported $491M of IRulya Therapeutics Inc. Common Stock stock for Q4 2020, down 41% quarter-over-quarter.
- 21 funds opened new IRulya Therapeutics Inc. Common Stock positions in Q4 2020 and 16 closed out, a net change of +5 holders.
- The largest IRulya Therapeutics Inc. Common Stock buyer in Q4 2020 was State Street, an estimated $23.8M added.
- The largest IRulya Therapeutics Inc. Common Stock seller in Q4 2020 was Citadel Advisors, an estimated $9.83M sold.
Based on aggregated 13F filings for Q4 2020.